Medical AI company VUNO said Thursday that it and Severance Cardiovascular Hospital have signed a memorandum of understanding to research and develop a solution to diagnose and manage transthyretin amyloid cardiomyopathy (ATTR-CM), one of the rare heart diseases.
VUNO has conducted research to detect ATTR-CM patients and confirm their risks at the request of global pharma company Pfizer since 2021. The OU with Severance Cardiovascular Hospital was also promoted for the smooth performance of its study.
Under the contract, VUNO and Severance Cardiovascular Hospital will embark on the development of software to detect ATTR-CM by analyzing the electrocardiogram (ECG) data based on AI deep learning technology.
“As ECG data has a high potential as the clue for various heart-related diseases, we will continue to strive to heighten the value of artificial intelligence in the medical area by seeking collaboration with global pharma companies and medical institutions,” VUNO CEO Lee Ye-ha said.
Related articles
- VUNO’s device warns against cardiac arrest in pediatric inpatients: study
- [RSNA 2022] 'VUNO will use US branch to get FDA nod for brain MRI, lung CT’
- VUNO’s AI-backed fundus reader wins nod in Taiwan
- VUNO to co-develop medical content with Weknew
- VUNO shares surge after FDA innovative medical device designation
- VUNO founder launches AI eye disease management startup
- AI-powered cardiac arrest prediction system saved this patient's life.
- J&J MedTech Korea to co-promote Huinno’s ECG monitoring patch with Yuhan Corp